Noninvasive preeclampsia prediction using plasma cell-free RNA signatures.
Messenger ribonucleic acid (mRNA) is a molecule that contains the instructions to tell cells how to make proteins. mRNA is made by “reading” deoxyribonucleic acid (DNA), then is released into the cell where it tells the body’s amino acid how to make a specific protein. Once the mRNA is used, it breaks down and is released into a person’s blood stream. These broken-down products are called cell-free RNA. They are made up of several types of longer and shorter pieces of mRNA, miRNA (microRNA), and lncRNA (long non-coding RNA). A simple blood sample can show the presence of cell-free RNA, and how active certain genes have been based on their presence.
Cell-free RNA is a new class of biomarkers that show promise to help diagnose medical conditions like preeclampsia. Researchers hope that cell-free RNA could help detect issues with the function of the placenta prior to the onset of preeclampsia.
In this study, researchers looked at blood samples from 917 pregnant patients (all Han Chinese) - 715 with uncomplicated pregnancies and 202 with preeclampsia. 151 of the preeclampsia cases occurred before 37 weeks (“preterm preeclampsia”) and 78 cases happened before 34 weeks (“early-onset preeclampsia”). The blood samples were taken before the patients showed any signs or symptoms of the disease. They found that a few mRNA, miRNA, and lncRNA markers difference between patient who had preeclampsia and those who did not. They also found differences between preterm and early-onset preeclampsia.
The researchers developed a prediction tool based on two clinical factors – in vitro fertilization (IVF) and mean arterial blood pressure – and 13 cell-free RNA patterns. In a group of patients with these risk factors and DNA/mRNA patterns, they found that 68% of them would be likely to develop preeclampsia, and 73% would develop early-onset preeclampsia (what is known as positive predictive value, or PPV).
The study identified 77 genes that were different between patients who had preeclampsia and those who did not. Many of these genes were ones previously shown to be involved in preeclampsia. However, the study was limited by the fact that it was studied in patients with similar ancestry. More research will be needed to further prove whether this could be developed into a clinical tool.
Take Home Message: Measurement of 13 cell-free RNA patterns from a pregnant person’s blood and two clinical features (IVF and mean arterial pressure) can predict the development of preeclampsia better than previous predictions tools. With further research these findings may help understand how preeclampsia occurs, and to design more effective treatments. However, the results need to be validated in prospective studies and in more diverse populations before they can be used clinically.
Citation: Zhou S, Li J, Yang W, Xue P, Yin Y, Wang Y, Tian P, Peng H, Jiang H, Xu W, Huang S, Zhang R, Wei F, Sun HX, Zhang J, Zhao L. Noninvasive preeclampsia prediction using plasma cell-free RNA signatures. Am J Obstet Gynecol. 2023 May 19:S0002-9378(23)00323-X. doi: 10.1016/j.ajog.2023.05.015. Epub ahead of print. PMID: 37211139.
Each quarter, our team of science writers reviews the most current research studies related to hypertensive disorders of pregnancy and summarizes those studies of greatest interest and potential impact to our community, including research studies related to risk assessment, diagnosis, prevention, and treatment. Special thanks to our volunteer research team, who under the leadership of Dr. Elizabeth Sutton, make Research Roundup possible, and to our Patient Advisory Council, who reviews these materials from the patient perspective.
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
The Preeclampsia Foundation's published research results.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
Preeclampsia Foundation Canada has announced that Kylie Belchamber, PhD of University of Birmingham, and Serena Gundy, MD, FRCP of McMaster University, are their 2023 Vision Grant research award recip...
Amit Zeisel, PhD and Ido Solt, MD and their research team at the Technion – Israel Institute of Technology and Rambam Hospital, together with Prof. Simcha Yagel, MD of Hadassa Hospital, have pub...
Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials Finding strategies for preventing preeclampsia is a top priority in...
Masked Pregnancy-Associated Hypertension as a Predictor of Adverse Outcomes Pregnant women who have risk factors for preeclampsia may be advised by their health care provider to monitor their...
Preeclampsia Prevention by Timed Birth at Term In this study, researchers looked at different ways to find out if a pregnant woman might get preeclampsia at term (>37 weeks) and when would be...